Columbus, OH Clinical Trials Report — April 2026

For patients and healthy volunteers in Columbus, OH, April 2026 presents a critical window to engage with clinical research, particularly for studies nearing their enrollment deadlines. Across the city, 79 clinical trials are scheduled to conclude within the next 90 days. This urgency is especially relevant for those without specific health conditions, as 10 of these rapidly closing studies are still actively seeking healthy volunteers. Individuals interested in contributing to medical advancements should explore these opportunities promptly.

Impending Deadlines for Specific Conditions

Patients managing certain health conditions also face impending deadlines to join research. Trials focused on various cancers, metabolic disorders, and cardiovascular health are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Stage III pancreatic cancer AJCC v8 (2 trials)
• Gestational diabetes (2 trials)
• PTSD (2 trials)
• Stage IV lung cancer AJCC v8 (2 trials)
• Recurrent endometrial carcinoma (2 trials)
• Primary peritoneal cancer (2 trials)
• Amyotrophic lateral sclerosis (1 trial)
• Ambulatory heart failure, NYHA class IV (1 trial)
• Adult congenital heart disease (1 trial)
• Aortic insufficiency (1 trial)

New Research Opportunities in Columbus

This month, Columbus saw the opening of 7 new clinical trials, a decrease from the 12 trials that launched in March 2026. Despite this dip, the city remains a dynamic center for medical research, with a total of 1,288 clinical trials currently recruiting across 366 research facilities. These new studies are exploring a range of conditions, including irritable bowel syndrome with diarrhea, pancreatic cystic neoplasm, uveitis in children, solid tumors, opioid overdose, kidney stones, and procedures like bone grafting and sinus lifting.

April brings several notable new trials to Columbus, including significant Phase 2 and 3 studies from major sponsors. These trials offer participants the chance to engage with cutting-edge treatments and diagnostic approaches across various health challenges.

• Incyte Corporation is sponsoring NCT07522073, "A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma." This important Phase 3 oncology trial, aiming for 588 participants, evaluates the efficacy and safety of a new combination therapy for metastatic pancreatic cancer.
• Eli Lilly and Company is initiating NCT07545759, "A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D)." This Phase 2 study, designed for 531 participants, will assess the tolerability, side effects, safety, and efficacy of brenipatide administered subcutaneously for IBS-D.
• The Ohio State University Comprehensive Cancer Center is leading NCT07529483, "Endoscopic Ultrasound-Guided Chemoablation for the Treatment of Pancreatic Cysts." This Phase 2 trial tests the effect of EUS-guided chemoablation in treating patients with pancreatic cysts, a crucial area given the challenges of early pancreatic cancer diagnosis. This study plans to enroll 35 participants.
• The Jaeb Center for Health Research is sponsoring NCT07518134, "A Study of Uveitis in Children <18 Years of Age." This observational study, involving 300 participants, aims to collect data on the clinical features and treatments for uveitis in children, helping to understand the frequency of uveitis subtypes and their characteristics.

Opportunities for Healthy Volunteers

For individuals without a specific medical condition, there are significant opportunities to contribute to medical research. Of the 7 new trials launched this month, 1 is actively seeking healthy volunteers. More broadly, Columbus currently has 103 clinical trials recruiting healthy participants, providing numerous avenues for those interested in supporting medical science. Remember, 10 of these healthy volunteer trials are closing within the next 90 days, so prompt action is encouraged.

Columbus's Research Powerhouses

Columbus is home to several leading research institutions that consistently run a high volume of clinical trials. These facilities are key destinations for individuals seeking to participate in medical research:

• Ohio State University Comprehensive Cancer Center (234 trials)
• Nationwide Children's Hospital (188 trials)
• The Ohio State University (134 trials)
• Ohio State University (116 trials)
• The Ohio State University Wexner Medical Center (69 trials)
• Riverside Methodist Hospital (42 trials)
• Grant Medical Center (37 trials)
• Doctors Hospital (34 trials)
• Research Site (34 trials)
• The Mark H Zangmeister Center (30 trials)
• Mount Carmel East Hospital (29 trials)
• Columbus Oncology and Hematology Associates Inc (27 trials)

These institutions offer a broad spectrum of research, from oncology at the Ohio State University Comprehensive Cancer Center and The Mark H Zangmeister Center, to pediatric care at Nationwide Children's Hospital, and diverse medical fields across The Ohio State University and its Wexner Medical Center.

Expanding Your Search Beyond Columbus

While Columbus offers a substantial array of clinical trial opportunities, individuals may also find options in nearby communities within Ohio. Cities with active trials include Cleveland (9 trials), Cincinnati (8 trials), Akron (2 trials), Youngstown (2 trials), Canal Winchester (1 trial), Canfield (1 trial), Canton (1 trial), and Bay Village (1 trial).

Who Can Participate?

Participation in clinical trials is open to a diverse range of individuals. Of the 7 new trials launched this month, 2 include children and 5 include older adults, ensuring that these populations have opportunities to contribute to medical science. Academic institutions, including Ohio State University and the Ohio State University Comprehensive Cancer Center, continue to play a vital role in Columbus's research ecosystem, sponsoring 4 of the new trials. Industry sponsors like Eli Lilly and Company, Incyte Corporation, and Purdue Pharma LP are also driving significant research efforts, sponsoring 3 new trials this month.

As we move further into spring, the focus will remain on the ongoing enrollment in these significant studies and the continued exploration of new therapeutic strategies, with Columbus's robust research community at the forefront of medical innovation.